EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 123 filers reported holding EXELIXIS INC in Q2 2015. The put-call ratio across all filers is 3.67 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $13,084,000 | +15.3% | 877,536 | -1.1% | 0.02% | +7.1% |
Q3 2016 | $11,345,000 | +65.0% | 887,034 | +0.7% | 0.01% | +55.6% |
Q2 2016 | $6,877,000 | +109.6% | 880,601 | +7.3% | 0.01% | +125.0% |
Q1 2016 | $3,281,000 | -26.8% | 820,346 | +3.2% | 0.00% | -33.3% |
Q4 2015 | $4,482,000 | +1.1% | 794,714 | +0.5% | 0.01% | 0.0% |
Q3 2015 | $4,435,000 | +69.1% | 790,552 | +13.3% | 0.01% | +100.0% |
Q2 2015 | $2,623,000 | +90.3% | 697,676 | +30.1% | 0.00% | +50.0% |
Q1 2015 | $1,378,000 | +77.6% | 536,366 | -0.4% | 0.00% | +100.0% |
Q4 2014 | $776,000 | -24.1% | 538,659 | -19.4% | 0.00% | 0.0% |
Q3 2014 | $1,023,000 | -53.1% | 668,659 | +3.8% | 0.00% | -66.7% |
Q2 2014 | $2,183,000 | +14.4% | 643,952 | +19.5% | 0.00% | 0.0% |
Q1 2014 | $1,908,000 | -38.3% | 538,943 | +6.8% | 0.00% | -40.0% |
Q4 2013 | $3,092,000 | +3.0% | 504,470 | -2.2% | 0.01% | 0.0% |
Q3 2013 | $3,001,000 | +35.0% | 515,714 | +5.3% | 0.01% | +25.0% |
Q2 2013 | $2,223,000 | – | 489,560 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 11,275,871 | $254,722,000 | 71.55% |
GREAT POINT PARTNERS LLC | 1,201,100 | $27,133,000 | 5.61% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 886,534 | $20,027,000 | 5.30% |
Sargent Investment Group, LLC | 498,350 | $11,258,000 | 2.96% |
CAPITAL MANAGEMENT CORP /VA | 311,660 | $7,040,000 | 1.57% |
EULAV Asset Management | 2,460,000 | $55,571,000 | 1.49% |
CM Management, LLC | 80,000 | $1,807,000 | 1.34% |
Integral Health Asset Management, LLC | 200,000 | $4,518,000 | 1.29% |
FARALLON CAPITAL MANAGEMENT LLC | 10,750,000 | $242,843,000 | 1.21% |
Sofinnova Investments, Inc. | 839,181 | $18,957,000 | 1.14% |